US imposes 100% tariff on imported pharmaceuticals, targeting Australia and global exporters
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025, targeting global exporters including Australia. The move, enacted under national security powers, aims to reshoring drug production to the US and address what the administration calls unfair pricing disparities, particularly with Australia’s Pharmaceutical Benefits Scheme (PBS), which keeps drug prices lower for Australians than Americans. Australia exported around $1.3–$2 billion in pharmaceuticals to the US in 2025, with CSL, the country’s largest biotech firm, producing most of these exports. CSL has invested heavily in US manufacturing and may qualify for exemptions or reduced tariffs due to its existing facilities and plasma-derived therapies, which meet urgent US health needs. The tariff applies only to patented drugs, not generics, and offers incentives for companies to relocate production to the US, reducing tariffs to 20% or eliminating them entirely if they secure ‘most favoured nation’ drug pricing status. Other countries like the EU, Japan, and the UK have negotiated lower tariff rates (10–15%), while Australia faces the full 100% rate despite its long-standing free trade agreement with the US. The Australian government, led by Health Minister Mark Butler, has firmly rejected pressure to alter the PBS, calling it a cornerstone of healthcare that has served Australians for 80 years. Opposition Leader Angus Taylor has pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters. The move follows Trump’s broader push to reshape global supply chains and reduce reliance on foreign manufacturing, despite a February 2025 Supreme Court ruling invalidating his earlier ‘Liberation Day’ tariffs. Critics argue the tariffs could disrupt global pharmaceutical supply chains and increase costs for US consumers, while supporters see it as a necessary step to protect national security and domestic industries.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025.
- Australia exported $US1.32 billion (or approximately $US1.3 billion–$US2 billion depending on source) in pharmaceuticals to the US in 2025, with CSL accounting for the bulk of these exports.
- CSL has US manufacturing facilities in Illinois and North Carolina, and recently announced a $US1.5 billion expansion of its Illinois factory (completed by 2031), with plasma-derived therapies exempt from tariffs if they meet urgent US health needs.
- The tariff applies only to patented drugs, not generic medicines, and is enacted under Section 232 of the Trade Expansion Act, avoiding the Supreme Court’s February 2025 ruling on ‘Liberation Day’ tariffs.
- Companies can reduce tariffs to 20% by moving production to the US or to zero by securing ‘most favoured nation’ drug pricing status for the US, with large companies given 120 days and smaller firms 180 days to comply.
- Australia’s Pharmaceutical Benefits Scheme (PBS) subsidizes drug prices lower than those in the US, which the Trump administration has criticized as undermining ‘most favoured nation’ pricing rules.
- Japan, the EU, South Korea, Switzerland, and Liechtenstein face 15% tariffs, while the UK has negotiated a 10% tariff with potential for future reduction to zero.
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it ‘not for sale’ and a ‘world-leading’ system serving patients for 80 years.
- Opposition Leader Angus Taylor (Coalition) pledged to work with the government to overturn the tariffs or secure exemptions for Australian exporters.
Points of Difference
Details reported by only one source:
- CSL’s bulk of Australian exports are made in Melbourne, but the company has invested heavily in US manufacturing to mitigate tariff risks.
- The tariff applies to patented products only, with a specific mention of CSL’s blood plasma products potentially qualifying for exemptions if they meet urgent US health needs.
- The White House official mentioned pharmaceutical companies could negotiate deals with the White House to lower US prices and avoid levies, referencing AstraZeneca’s pre-existing deals.
- The tariff was invoked under national security powers, with Trump stating it addresses ‘threatened impairment of the national security’ from pharmaceutical imports.
- The tariff adjustment for steel-containing products (50% to 25% or zero depending on steel content) was mentioned as a secondary detail.
- The tariff announcement was timed to mark one year since Trump’s ‘Liberation Day’ tariffs (February 2025), which were later struck down by the Supreme Court.
- A White House official explicitly stated Australia does not have a ‘special pharma tariff rate’ despite long-standing trade ties.
- The tariff reduction timeline for new facilities is tied to completion by January 2029 (end of Trump’s term).
- The text of the executive order was described as focusing on ‘deals that had already been made’ with companies like CSL, Austria, and France.
- Health Minister Mark Butler called the decision ‘deeply disappointing and deeply concerning’ in a direct quote.
- The Guardian emphasized Trump’s broader goal of forcing manufacturers to ‘commit to making their products domestically’ or agree to drug-pricing deals.
- The article highlighted that American consumers pay far more for prescription medicines than Australians due to the PBS, framing this as a key frustration for Trump.
- Trump previously suggested the tariff could be as high as 200%, but ultimately set it at 100%.
- The ABC noted that CSL’s plasma therapies are made entirely from US-sourced plasma, which may help secure exemptions.
- A senior administration official stated that too many drugs ‘driven by research and development in America’ are now produced abroad, making the US ‘beholden to these other countries.’
- The ABC mentioned that 17 deals worth hundreds of billions of dollars in manufacturing had already been negotiated to move production to the US.
- The SMH repeated details from THEAGE and THEGUARDIAN verbatim, with no additional unique information.
Contradictions
Conflicting information between sources:
- NEWSCOMAU states CSL’s bulk of Australian exports are made in Melbourne, while THEAGE and ABC emphasize CSL’s significant US manufacturing capacity and recent $US1.5 billion expansion in Illinois.
- THEAGE and ABC mention Trump’s tariff could have been as high as 200%, but NEWSCOMAU and GUARDIAN only reference the final 100% rate without mentioning the 200% possibility.
- NEWSCOMAU claims the tariff applies to patented products only, but ABC and GUARDIAN do not explicitly state this distinction in their summaries.
- THEAGE and ABC state the tariff is tied to completion of new facilities by January 2029, but NEWSCOMAU does not mention this deadline explicitly.
- GUARDIAN and ABC highlight that American consumers pay far more for prescription medicines than Australians, while NEWSCOMAU and THEAGE focus more on the tariff’s impact on Australian exporters and PBS negotiations.
Source Articles
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....